FDA Grants New Indication to Xarelto to Reduce Major CV Events

The FDA granted a new indication to rivaroxaban (Xarelto) to reduce the risk for major cardiovascular events, such as CV death, myocardial infarction and stroke, in people with chronic coronary or peripheral artery disease.